Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries,October 2021 to March 2022

By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65–79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant.     

Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency

A prophylactic hepatitis C virus (HCV) vaccine that elicits neutralizing antibodies could be key to HCV eradication. However, the genetic and antigenic properties of HCV envelope (E1E2) proteins capable of inducing anti-HCV broadly neutralizing antibodies (bNAbs) in humans have not been defined. Here, we investigated the development of bNAbs in longitudinal plasma of HCV-infected persons with persistent infection or spontaneous clearance of multiple reinfections. By measuring plasma antibody neutralization of a heterologous virus panel, we found that the breadth and potency of the antibody response increased upon exposure to multiple genetically distinct infections and with longer duration of viremia. Greater genetic divergence between infecting strains was not associated with enhanced neutralizing breadth. Rather, repeated exposure to antigenically related, antibody-sensitive E1E2s was associated with potent bNAb induction. These data reveal that a prime-boost vaccine strategy with genetically distinct, antibody-sensitive viruses is a promising approach to inducing potent bNAbs in humans.     

Glomus‐like bodies within a neurofibroma: a novel neoplasm arising in neurofibromatosis type 1 or a coincidence?

Neurofibromatosis type 1 is a relatively common genetic disorder with variable phenotypes. Tumors with features of both glomus tumors and neurofibromas are exceedingly rare in literature. Herein, we report a not yet described neoplasm with features of both a glomangioma/glomus tumor and a neurofibroma arising in a patient with segmental neurofibromatosis. Our case report supports the theory of a common lineage/ancestor cell between neurofibromas and glomus tumors and adds it to the spectrum of neoplasms that may arise in the setting of Von Recklinghausen's disease.     

Electrophysiological responses to regularity show specificity to global form: The case of Glass patterns

The holographic weight of evidence model (van der Helm & Leeuwenberg, J Math Psychol, 35, 1991, 151; van der Helm & Leeuwenberg, Psychol Rev, 103, 1996, 429) estimates that the perceptual goodness of moiré structures (Glass patterns), irrespective of their global form, is comparable to that of reflection symmetry. However, both behavioural and neuroscience evidences suggest that certain Glass forms (i.e. circular and radial structures) are perceptually more salient than others (i.e. translation structures) and may recruit different perceptual mechanisms. In this study, we tested whether brain responses for circular, radial and translation Glass patterns are comparable to the response for onefold bilateral reflection symmetry. We recorded an event‐related potential (ERP), called the sustained posterior negativity (SPN), which has been shown to index perceptual goodness of a range of regularities. We found that circular and radial Glass patterns generated a comparable SPN amplitude to onefold reflection symmetry (in line with the prediction of the holographic model), starting approx. 180 ms after stimulus onset. Conversely, the SPN response to translation Glass patterns had a longer latency (approx. 400 ms). These results show that Glass patterns are a special case of visual regularity, and perceptual goodness may not be fully explained by the holographic identities that constitute it. Specialised processing mechanisms might exist in the regularity‐sensitive extrastriate areas, which are tuned to global form configurations.     

Did the COVID‐19 pandemic silence the needs of people with epilepsy?

Aims. The COVID‐19 pandemic shook European healthcare systems, with unavoidable gaps in the management of patients with chronic diseases. We describe the impact of the pandemic on epilepsy care in three tertiary epilepsy centres from Spain and Italy, the most affected European countries. Methods. The three epilepsy centres, members of the European EpiCARE network, manage more than 5,700 people with epilepsy. In Bologna and Barcelona, the hospitals housing the epilepsy centres were fully converted into COVID‐19 units. We describe the reorganization of the clinics and report on the frequency of SARS‐CoV‐2 in people with epilepsy as well as the frequency of seizures in patients admitted to the COVID units. Finally, we elaborate on critical issues regarding the second phase of the pandemic. Results. The activities related to epilepsy care were reduced to less than 10% and were deprioritized. Discharges were expedited and elective epilepsy surgeries, including vagal nerve stimulator implantations, cancelled. Hospitalizations and EEG examinations were limited to emergencies. The outpatient visits for new patients were postponed, and follow‐up visits mostly managed by telehealth. Antiseizure medication weaning plans and changes in vagal nerve stimulator settings were halted. Among the 5,700 people with epilepsy managed in our centres, only 14 tested positive for SARS‐CoV‐2, without obvious impact on their epilepsy. None of the 2,122 patients admitted to COVID units experienced seizures among the early symptoms. Conclusion. Epilepsy care was negatively impacted by the pandemic, irrespective of COVID‐19 epidemiology or conversion of the hospital into a COVID‐19 centre. The pandemic did not silence the needs of people with epilepsy, and this must be considered in the planning of the second phase.